US 11903994
Dosing regimens
granted A61KA61K38/00A61K47/595
Quick answer
US patent 11903994 (Dosing regimens) held by Apellis Pharmaceuticals, Inc. expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Apellis Pharmaceuticals, Inc.
- Grant date
- Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K38/00, A61K47/595, A61K47/60, A61K47/64